Toxic shock syndrome secondary prevention: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
====Secondary Prevention==== | ====Secondary Prevention==== | ||
{{Toxic Shock Syndrome}} | |||
{{CMG}};{{AE}}{{MIR}} | |||
*'''First Sentences:''' | *'''First Sentences:''' | ||
:Secondary prevention strategies following [disease name] include [strategy 1], [strategy 2], and [strategy 3]. | :Secondary prevention strategies following [disease name] include [strategy 1], [strategy 2], and [strategy 3]. |
Revision as of 15:34, 15 May 2017
Secondary Prevention
Template:Toxic Shock Syndrome Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]
- First Sentences:
- Secondary prevention strategies following [disease name] include [strategy 1], [strategy 2], and [strategy 3].
OR
- The primary and secondary prevention strategies for [Disease Name] are the same.
Chemoprophylaxis of household contacts of STSS patients: Household contacts of people with STSS have a higher risk of invasive GAS infection compared to the general population. The Centers for Disease Control and Prevention have not made definite recommendations; some authors have recommended a 10-day course of cephalosporin
The risk of secondary cases of invasive disease is low at 2.9 per 1000. [null [82]] Several regimens have been successful in eradicating group A streptococcus from the pharynx of chronic carriers (i.e., rifampin plus intramuscular benzathine penicillin or a 10-day course of a second-generation cephalosporin or clindamycin). [null [107]] However, there are limited data concerning chemoprophylaxis for severe invasive group A streptococcal or staphylococcal infections.
American Academy of Pediatrics. Severe invasive group A streptococcal infection: a subject review. Pediatrics. 1998;101:136-140
Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group a streptococci. J Pediatr. 1991;119:123-128